Mirae Asset Global Investments Co. Ltd. Sells 300 Shares of Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. cut its holdings in Repligen Corporation (NASDAQ:RGEN) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,522 shares of the biotechnology company’s stock after selling 300 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.05% of Repligen worth $3,672,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Congress Asset Management Co. raised its position in shares of Repligen by 18.0% in the 2nd quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after acquiring an additional 23,231 shares in the last quarter. Park Avenue Securities LLC bought a new position in shares of Repligen in the 2nd quarter worth about $340,000. Krilogy Financial LLC bought a new stake in Repligen in the 2nd quarter valued at about $2,513,000. Osterweis Capital Management Inc. increased its position in Repligen by 18.0% in the 1st quarter. Osterweis Capital Management Inc. now owns 72,765 shares of the biotechnology company’s stock valued at $9,259,000 after buying an additional 11,080 shares in the last quarter. Finally, Strs Ohio bought a new stake in Repligen in the 1st quarter valued at about $6,069,000. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research analyst reports. Barclays boosted their target price on Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Jefferies Financial Group decreased their target price on Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, September 12th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. Finally, Hsbc Global Res raised Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Stock Performance

Shares of RGEN opened at $145.93 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The stock has a 50 day moving average price of $123.40 and a two-hundred day moving average price of $125.50. The firm has a market capitalization of $8.21 billion, a P/E ratio of -583.70, a P/E/G ratio of 2.77 and a beta of 1.08. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.